250358-67-9

Upstream product

• 3646-73-9 α-D-galactopyranose 
• 10257-28-0 D-Galactose 
• 59-23-4 D-Galactose 
• 250358-65-7 2-bromoethyl α-D-galactopyranoside 
• 86651-40-3 2'-bromoethyl-2,3,4,6-tetra-O-acetyl-α-D-galactopyranoside 
• 250358-66-8 2 '-thioethyl-α-D-galactopyranoside 

Relevant academic research and scientific papers

Convergent synthesis of fluorescein-labelled lysine-based cluster glycosides

The synthesis of fluorescein-labelled lysinyl trees, containing 2, 4 or 8 manno- or galactoside residues, is reported. These lysine-based cluster glycosides have been readily assembled by coupling amino-functionalized, N-chloroacetylated-L-lysinyl trees w

NANOPARTICLE-BASED THERAPY OF INFLAMMATORY DISORDERS

The present invention provides a nanoparticle comprising: a core comprising a metal and/or a semiconductor; and a plurality of ligands covalently linked to the core, wherein said ligands comprise: (i) at least one dilution ligand comprising a carbohydrate, glutathione or a polyethyleneglycol moiety; and (ii) a ligand of the formula MTX-L-, wherein MTX-L-represents methotrexate coupled to said core via a linker L. Also provided are pharmaceutical compositions of the nanoparticle, including gel formulations, and medical uses of the nanoparticle and pharmaceutical compositions, including for the treatment of an inflammatory or autoimmune disorder, such as psoriasis.

ANTIFOLATE-CARRYING NANOPARTICLES AND THEIR USE IN MEDICINE

The present invention provides a nanoparticle comprising: a core comprising a metal and/or a semiconductor; and a plurality of ligands covalently linked to the core, wherein said ligands comprise: (i) at least one dilution ligand comprising a carbohydrate, glutathione or an ethylene glycol-containing moiety; and (ii) a ligand of the formula D-L1-Z-L2, wherein D comprises an antifolate drug or folic acid, L1 comprises a first linker portion comprising a C2-C12 glycol and/or C2-C12 alkyl chain, L2 comprises a second linker portion comprising a C2-C12 glycol and/or C2-C12 alkyl chain, wherein L1 and L2 may be the same or different, and wherein Z represents a carbonyl-containing group linking L1 and L2, and wherein L2 is coupled to said core, Also provided are pharmaceutical compositions comprising such nanoparticles, medical uses thereof and methods for producing the nanoparticles.

NANOPARTICLES AND THEIR USE IN CANCER THERAPY

The present invention provides a nanoparticle comprising a core comprising a metal; and a corona comprising a plurality of ligands covalently linked to the core, the plurality of ligands including at least a first species of ligand comprising an ethylene glycol portion and an amine group and at least a second species of ligand comprising a carbohydrate group, for use in a method of treating a cancer, particularly skin cancer, in a mammalian subject. Also disclosed are methods of treatment by administering the nanoparticles alone or in combination with radiotherapy.

COMBINATION PEPTIDE-NANOPARTICLES AND DELIVERY SYSTEMS INCORPORATING SAME

Nanoparticles having a core and a corona of ligands covalently linked to the core, wherein differing species of peptides are bound to the nanoparticles and incorporated into various dosage forms.

NANOPARTICLE PEPTIDE COMPOSITIONS

The present invention relates to amylin peptide-carrying nanoparticles, particularly for use in medicine, and includes methods for treatment of disorders, e.g., of blood glucose regulation. Nanoparticle composition comprise a nanoparticle comprising a core comprising a metal and/or a semiconductor; and a corona comprising a plurality of ligands covalently linked to the core, wherein said ligands comprise glutathione; and at least one amylin peptide that is non-covalently bound to the corona.

Synthesis of Clustered Glycoside - Antigen Conjugates by Two One-Pot, Orthogonal, Chemoselective Ligation Reactions: Scope and Limitations

Major histocompatibility class II antigens have been bound to clustered glycosides for selective targeting of the dendritic cell mannose receptor. Di-, tetra-, and octavalent glycoside - antigen conjugates have been obtained after two, orthogonal, hydrazo